Hunter C. Smith - 12 Nov 2021 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Director
Signature
/s/ Steven Weber, by power of attorney
Issuer symbol
AGLE
Transactions as of
12 Nov 2021
Transactions value $
$0
Form type
4
Filing time
16 Nov 2021, 15:34:18 UTC
Next filing
11 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Director Stock Option (right to buy) Award $0 +60,000 $0 60,000 12 Nov 2021 Common Stock 60,000 $7.04 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable in 36 equal monthly installments beginning on December 12, 2021 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.